In vitro diagnostics can detect diseases/conditions, and can be used to monitor overall health to help cure, treat, and/or prevent diseases. In vitro diagnostics are utilized to diagnose a wide range of medical disorders, such as cardiovascular disease, cancer, diabetes, infectious disease, nephrology, autoimmune diseases, and HIV/AIDS. IVD are tests done on the blood sample or tissue sample that have been taken from the human body. In short, IVD raw materials used to determine the status of a person's health. The core raw materials of in vitro diagnostic (IVD) reagents/kits include antibodies, antigens, enzymes, etc., which are important determinants of the quality and effectiveness of the reagents/kits.
Market Dynamics:
The outbreak of COVID-19, high prevalence of chronic diseases, advanced technologies in in vitro diagnostic products, rise in use of point-of-care diagnostics, rising geriatric population, and growing significance of companion diagnostics are some major factors expected to boost the growth of the global IVD raw materials market during the forecast period.
In August 2021, Roche received the U.S. Food and Drug Administration (FDA) approval for VENTANA MMR RxDx Panel to identify dMMR solid tumor patients eligible for anti-PD-1 immunotherapy. Moreover, in May 2020, ERBA Diagnostics Mannheim GmbH announced the launch of its immunoassay-based kit, ErbaLisa COVID-19 ELISA kits, for the detection of IgG and IgM antibodies to SARS-CoV-2. In March 2020, Abbott launched the RealTime SARS-CoV-2 assay, a PCR-based test, for the diagnosis of COVID-19, and BioMedomics launched a point-of-care COVID-19 test that can detect antibodies in blood within 15 minutes.
Key features of the study:
Detailed Segmentation:
Table of Contents:
*Browse 24 market data tables and 28 figures on "Global IVD Raw Materials Market” - forecast to 2028
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients